Seth Lederman - Feb 27, 2024 Form 4/A Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role: Chief Executive Officer, Director
Signature: /s/ Seth Lederman
Stock symbol: TNXP
Transactions as of: Feb 27, 2024
Transactions value $: $0
Form type: 4/A
Date filed: 3/6/2024, 05:01 PM
Date Of Original Report: Feb 29, 2024
Previous filing: Feb 24, 2023
Next filing: Feb 27, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNXP	Stock Option	Award	$0	+235K		$0.00	235K	Feb 27, 2024	Common Stock	235K	$0.37	Direct	F1, F2
transaction	TNXP	Stock Option	Award	$0	+1.9M		$0.00	1.9M	Feb 27, 2024	Common Stock	1.9M	$0.46	Direct	F1, F2
transaction	TNXP	Stock Option	Award	$0	+1.31M		$0.00	1.31M	Feb 27, 2024	Common Stock	1.31M	$0.37	Direct	F2, F3

Showing 1 to 3 of 3 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2	The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
F3	The amendment corrects the Conversion or Exercise Price of from $0.0368 to $0.368.